Endothelial derived relaxing factor controls renal hemodynamics in the normal rat kidney
- PMID: 2103847
- DOI: 10.1681/ASN.V16875
Endothelial derived relaxing factor controls renal hemodynamics in the normal rat kidney
Abstract
These studies were conducted in the conscious, chronically catheterized rat to determine whether the endothelial derived relaxing factor (EDRF) controls renal function in the normal state. Administration of the EDRF synthesis inhibitors N-monomethyl-L-arginine (NMA; 100 mg/kg body weight) or N-nitro-L-arginine methylester (NAME; 10 mg/kg body wt) led to a large, sustained rise in blood pressure, a large rise in renal vascular resistance, a fall in renal plasma flow, a relatively slight reduction in glomerular filtration rate, and a consequent rise in filtration fraction. In addition, a marked natriuresis occurred because of a reduction in the fractional reabsorption of sodium. In separate studies, a continuous infusion of excess L-arginine (300 mg/kg body wt bolus followed by 50 mg/kg body wt per min) attenuated the NMA- or NAME-induced rise in blood pressure and reversed the renal hemodynamic effects such that a significant rise in renal plasma flow was seen. L-Arginine alone produced a selective renal vasodilation and large increases in sodium excretion. These observations support earlier suggestions that tonic release of EDRF controls the basal blood pressure and also show that renal function in the normal unstressed rat is markedly influenced by EDRF. These studies suggest that, in addition to controlling renal plasma flow, EDRF may have other, complex actions at the glomerulus. The natriuresis seen after acute inhibition of EDRF with NMA or NAME was probably the result of a pressure natriuretic response to the abrupt rise in blood pressure and also, perhaps, reflects removal of an EDRF influence to directly enhance sodium reabsorption somewhere in the nephron.
Similar articles
-
Role of endothelium-derived relaxing factor in the in vivo renal vascular action of adenosine in dogs.J Pharmacol Exp Ther. 1992 Mar;260(3):1262-7. J Pharmacol Exp Ther. 1992. PMID: 1545391
-
Locally produced EDRF controls preglomerular resistance and ultrafiltration coefficient.Am J Physiol. 1993 Feb;264(2 Pt 2):F212-5. doi: 10.1152/ajprenal.1993.264.2.F212. Am J Physiol. 1993. PMID: 8447434
-
Renal effects of acute endothelial-derived relaxing factor blockade are not mediated by angiotensin II.Am J Physiol. 1993 Jan;264(1 Pt 2):F74-8. doi: 10.1152/ajprenal.1993.264.1.F74. Am J Physiol. 1993. PMID: 8430832
-
Effects of amino acid infusion on renal hemodynamics. Role of endothelium-derived relaxing factor.Hypertension. 1991 Jun;17(6 Pt 2):1045-51. doi: 10.1161/01.hyp.17.6.1045. Hypertension. 1991. PMID: 2045148
-
Role of endothelium-derived relaxing factor in regulation of renal hemodynamic responses.Am J Physiol. 1990 Mar;258(3 Pt 2):H655-62. doi: 10.1152/ajpheart.1990.258.3.H655. Am J Physiol. 1990. PMID: 2156453
Cited by
-
Increased blood pressure in rats after long-term inhibition of the neuronal isoform of nitric oxide synthase.J Clin Invest. 1997 May 1;99(9):2212-8. doi: 10.1172/JCI119394. J Clin Invest. 1997. PMID: 9151793 Free PMC article.
-
Reduced renal responses to nitric oxide synthase inhibition in mice lacking the gene for gp91phox subunit of NAD(P)H oxidase.Am J Physiol Renal Physiol. 2008 Sep;295(3):F758-64. doi: 10.1152/ajprenal.90291.2008. Epub 2008 Jul 2. Am J Physiol Renal Physiol. 2008. PMID: 18596078 Free PMC article.
-
Endothelin and angiotensin mediate most glomerular responses to nitric oxide inhibition.Kidney Int. 1999 Jun;55(6):2390-6. doi: 10.1046/j.1523-1755.1999.00466.x. Kidney Int. 1999. PMID: 10354287 Free PMC article.
-
Changes of the plasma endothelin in adaptation to increased salt intake in rats.Korean J Intern Med. 1997 Jan;12(1):62-6. doi: 10.3904/kjim.1997.12.1.62. Korean J Intern Med. 1997. PMID: 9159040 Free PMC article.
-
Inhibition of endothelial derived relaxing factor (EDRF) aggravates ischemic acute renal failure in anesthetized rats.Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):305-10. doi: 10.1007/BF00169160. Naunyn Schmiedebergs Arch Pharmacol. 1993. PMID: 8232607
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous